Lexaria Bioscience Corp (LEXX) financials · rev $705.9K
Lexaria Bioscience Corp (LEXX) rev $705.9K.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $705.9K | $464.3K |
| Cost of Revenue | $2.7K | $4.8K |
| Gross Profit | $703.2K | $459.5K |
| Operating Income | -$11.9M | -$5.8M |
| Net Income | -$11.9M | -$5.8M |
| EPS (Diluted) | $-0.66 | $-0.47 |
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total Assets | $4.2M | $8.9M | $3.1M | $7.8M |
| Current Assets | $3.5M | $7.9M | $2.2M | $7.0M |
| Cash & Equivalents | $0 | $0 | $0 | $5.8M |
| Inventory | $0 | $0 | $0 | $38.4K |
| PP&E | $228.1K | $254.7K | $254.1K | $315.5K |
| Total Liabilities | $1.6M | $1.2M | $403.9K | $201.4K |
| Current Liabilities | $1.5M | $1.1M | $267.7K | $194.0K |
| Short-term Debt | $0 | $0 | $0 | $0 |
| Long-term Debt | $0 | $0 | $0 | $0 |
| Total Debt | $0 | $0 | $0 | $0 |
| Shareholders' Equity | $3.0M | $8.0M | $3.0M | $7.9M |
| Retained Earnings | -$63.5M | -$51.6M | -$45.8M | -$39.1M |
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating Cash Flow | -$10.5M | -$5.0M | -$5.9M | -$4.9M |
| CapEx | $24.6K | $43.0K | $33.7K | $49.2K |
| Investing Cash Flow | -$243.0K | -$188.6K | -$169.6K | -$180.6K |
| Financing Cash Flow | $6.0M | $10.3M | $1.6M | -$44.6K |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$4.7M | $5.1M | -$4.5M | $0 |
| Free Cash Flow | -$10.5M | -$5.0M | -$5.9M | -$4.9M |
FAQ
What is LEXX P/E and revenue?
Lexaria Bioscience Corp (LEXX) rev $705.9K.
What is LEXX revenue?
Lexaria Bioscience Corp last cached revenue is $705.9K (FY2025).
Is LEXX profitable?
Lexaria Bioscience Corp last cached net income is -$11.9M.
What are LEXX total assets?
Lexaria Bioscience Corp last cached total assets are $4.2M.
What is LEXX free cash flow?
Lexaria Bioscience Corp last cached free cash flow is -$10.5M.
Not investment advice. Cached statements, not a live tape.